GSK and Theravance submit Anoro to FDA as COPD drug

02/20/2013 | American City Business Journals

GlaxoSmithKline and Theravance said the FDA has accepted their new drug application for Anoro as a daily treatment for chronic obstructive pulmonary disease. Anoro, formerly known as UMEC/VI, is a combination of umeclidinium bromide, a long-acting muscarinic antagonist, and vilanterol, a long-acting beta-2 agonist. The FDA is expected to decide by Dec. 18.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT